We are proud and pleased to have received the award for the Best Market Data Service at the Systems in the City Fintech Awards during an online ceremony hosted on 10th September 2020. In addition, Ricky Strachan, Sales Manager at Infront in the UK, received an award for Sales Manager of the Year.
Who is the new Infront and what does it stand for?
Read the following interview about our new market positioning, our product strategy and how you will benefit from it. Kristian Nesbak, CEO of Infront, Florent Grauer as CPO of Infront and Afsheen Azam as Head of Customer Support, Europe at Infront will give you some insights.
Infront announced today that Ramsey Crookall, the Isle of Man’s longest-established independent stockbroker, has gone live with the Infront Professional Terminal, replacing their existing terminals across their trading and analyst desks.
We cordially invite you to the webinar "Customer Account | Postbox, Portfolio Access" on Tuesday, October 06, 2020 from 11:00 to 12:00. The event will be held in German language, please contact us, if you’re interested in an English version.
Customer Account is the digital solution for your customers:
An introduction is followed by live demonstrations and an overview of all available variants including a sneak preview of further development. Afterwards, we will of course be available to answer your questions.
Here you can register for the free webinar.
AM TECH DAY is the European market event dedicated to the impact of technological innovation on the asset management industry, gathering asset managers, wealth managers, asset owners, insurers and FinTechs. For its 11th year, the event will be held on 13 October at the Palais Brongniart, Paris.
The health crisis has made it more vital than ever to communicate, talk and work online, effectively boosting the value of all tools that can do this in a fast and secure way. It has also spurred their adoption throughout the asset management industry with the early adopters effectively providing a stress test for the sector.
At the same time, technologies continue to improve, giving professional investors a better handle on the key issues affecting sustainable development and helping them adopt best practice in transparency, equity and security.
Now more than ever, the asset management industry has the means and the opportunity to reinvent itself.
Meet Infront there: Palais Brongniart, 16 Place de la Bourse, at 10:00.
As in previous years, COPS invites to their annual COPS user meeting this year from 24 to 25 June 2021 at the Seehotel Rust in Rust on Neusiedlersee.
The customers can expect a versatile and varied program, ranging from innovations in software solutions, successful project reports to practical application examples.
As a strategic partner, COPS gives us the opportunity to present our company and our solutions and show-case the cooperation with COPS.
You can find further information here...
The SIPUGday focuses since the start on market data and related technologies, services and products in the front, back and middle office. Regulations and their impact on data are also a topic for our audience.
Infront and vwd will be represented on site by Ivo Bieri, Managing Director Switzerland. He will be happy to inform you about the advantages for you of the merger of the two companies in the future. We look forward to a lively exchange with you!
October 27, 2020
Further information will be available shortly here or under Quantalys Inside 2020.
We will again be represented at the DKF this year and look forward to your visit to our stand.
Further information will be available here soon or on the official DKF 2021 website.
24.09.2020 BUSINESS WIRE: Aera Technology gibt auf Global Customer Summit allgemeine Veröffentlichung seines Cognitive Operating System™ bekannt.
MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.Erhöhte Agilität in Zeiten der Disruption ist entscheidend für Lieferkettenentscheidungen MOUNTAIN VIEW, Kalifornien --(BUSINESS WIRE)-- 24.09.2020 --Aera Technology hat heute die allgemeine Verfügbarkeit des Aera...
24.09.2020 BUSINESS WIRE: Kioxia erhält den Imperial Invention Prize (kaiserlicher Erfindungspreis) der National Commendation for Invention 2020
MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.TOKIO --(BUSINESS WIRE)-- 24.09.2020 --Die Kioxia Corporation, ein weltweit führender Anbieter von Speicherlösungen, gab heute bekannt, dass das Unternehmen für seine Erfindung eines 3D-Flash-Speicherbausteins hoher...
24.09.2020 BUSINESS WIRE: DXC-Technologie ernennt Führungskräfte zur Unterstützung des „neuen DXC“
MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.TYSONS, Virginia, USA --(BUSINESS WIRE)-- 24.09.2020 --DXC Technology (NYSE:DXC) stellte heute seine jüngsten Ernennungen für Führungspositionen vor, die das DXC-Führungsteam weiter stärken werden. Die meisten von...
24.09.2020 BUSINESS WIRE: Science, Data, and Facts Should Unite Decision-Making, Says PMI CEO in Speech at Concordia Summit
MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.LAUSANNE, Switzerland --(BUSINESS WIRE)-- 24.09.2020 --André Calantzopoulos, CEO of Philip Morris International (PMI) (NYSE: PM), today delivered high-level remarks at the 2020 Concordia Annual Summit. Calantzopoulos...
24.09.2020 BUSINESS WIRE: NanoTemper Technologies veröffentlicht DLS-Funktion bei Prometheus Panta und ermöglicht so hochauflösende, bereichsspezifische Stabilitätscharakterisierungen für Biologika
MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.Prometheus, der neue Goldstandard, sorgt jetzt für Klarheit bei den anspruchsvollsten StabilitätscharakterisierungenSOUTH SAN FRANCISCO, Kalifornien --(BUSINESS WIRE)-- 24.09.2020 --NanoTemper Technologies, bekannt...
24.09.2020 BUSINESS WIRE: Swiss Medical Group Holding übernimmt CoreMedica Europe
MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.LUXEMBURG --(BUSINESS WIRE)-- 24.09.2020 --Die Swiss Medical Group (SMG) Holding Luxembourg SA, die für die Entwicklung von STARKS Age-Management in Europa und Asien massgeblich verantwortlich ist, gab die Übernahme...
19.09.2020 Mynewsdesk: #UnserHerzFürDieWiesn - Ein Gruß der Münchner Brauereien und der Oktoberfest-Familie in die Welt
Böllerschüsse und das „Ozapft is“ des Münchner Oberbürgermeister läuten normalerweise das Oktoberfest ein – nicht so 2020. Auf Initiative der Paulaner Brauerei, eine der sechs Münchner Traditionsbrauereien, die auf dem Oktoberfest ihr Bier ...
16.09.2020 Mynewsdesk: Welttag der Patientensicherheit 2020: VOD fordert Berufsgesetz für Osteopathen zum Schutz der Patienten
Eine berufsgesetzliche Regelung der Ausbildung und Ausübung fordert der Verband der Osteopathen Deutschland (VOD) e.V. anlässlich des Welttages der Patientensicherheit am 17. September 2020.Laut einer Forsa-Umfrage waren bereits rund 12 Millionen Bundesbürger in osteopathischer ...
15.09.2020 Mynewsdesk: Woche des Hörens 2020 vom 21. bis 26. September - Hören ist individuell!
FGH, 2020. – Die Einzigartigkeit des menschlichen Hörens steht im Mittelpunkt der diesjährigen Aktionswoche zur Hörgesundheit in Deutschland. Denn der Hörsinn ist so individuell wie ein Fingerabdruck. Jeder Mensch hört ein wenig anders und stellt deshalb auch ganz ...
11.09.2020 Mynewsdesk: Caravan Salon auf Messe.TV
Ob Wohnwagen oder Wohnmobil, für immer mehr Urlauber geht es mit dem eigenen Hotel auf die Reise. Die Reise- und Tourismusbranche sind von Corona und auch den damit einhergehenden politischen Maßnahmen schwer betroffen. Doch im Gegensatz zu anderen Bereichen geht ...
10.09.2020 Mynewsdesk: Starke Männer - starke Osteopathie / Verband der Osteopathen Deutschland (VOD) e.V.: 'Weltmeisterliche, abenteuerliche und atemberaubende Höchstleitungen'
Handwerker-Profis, Wüsten-Rallye-Fahrer und Fallschirmspringer-Asse schwören auf Osteopathie. Denn auch wenn man zuerst nicht daran denken würde: Gerade Männer mit Berufen und Hobbies mit starker körperlicher Beanspruchung minimieren Belastungen und rufen ...
02.09.2020 Mynewsdesk: Verband des Jahres 2020: BdS erhält Auszeichnung von der Deutschen Gesellschaft für Verbandsmanagement
Beim diesjährigen 17. Deutschen Verbändekongress der Deutschen Gesellschaft für Verbandsmanagement e.V. (DGVM): https://www.dgvm.de/, der am 1. und 2. September in Berlin stattfand, wurde der Bundesverband der Systemgastronomie e. V. als „Verband des Jahres 2020“ in der ...
13.08.2020 GlobeNewswire: Daridorexant Phase 3 results in insomnia to be presented at SLEEP 2020
Daridorexant Phase 3 results in insomnia to be presented at SLEEP 2020
Allschwil, Switzerland – August 13, 2020
Idorsia Ltd (SIX: IDIA) today announced that the positive results from the
first pivotal Phase 3 study investigating 25 and 50 mg doses of its dual orexin
receptor antagonist, daridorexant, in adult and elderly patients with insomnia,
are to be presented at SLEEP 2020 . Due to the COVID-19 pandemic, the
Associated Professional Sleep Societies (APSS) is turning SLEEP 2020, the
world’s largest meeting devoted entirely to clinical sleep medicine, and sleep
and circadian research, into a virtual meeting from August 27 – 30, 2020. The
meeting has live-streamed content as well as on-demand recorded sessions to
The abstract entitled “A Phase 3, Multi-Center, Double-Blind, Randomized,
Placebo-Controlled, Polysomnography Study to Assess Efficacy and Safety of
Daridorexant in Adult and Elderly Insomnia Patients” will be presented as an
oral presentation by Dr Thomas Roth, PhD, Director of the Sleep Disorder and
Research Center at Henry Ford Hospital, and will be available on demand to
registered attendees of SLEEP 2020 as part of the late-breaking program.
More information and the late breaking abstract is available in the Virtual
Sleep 2020 meeting guide .
The Phase 3 program design will also be presented as a poster entitled “0521 –
Daridorexant (ACT-541468), a dual orexin receptor antagonist for the treatment
of insomnia disorder: double blind, randomized, Phase 3 studies for efficacy
and safety in adult and elderly patients”. The poster will be available on
demand to registered attendees of SLEEP 2020 and the abstract can be found in
the Abstract Supplement .
In April and July 2020, Idorsia reported positive results in each of the two
pivotal Phase 3 studies of daridorexant in patients with insomnia. More details
and commentary can be found in the dedicated press releases ( first study
release ), ( second study release ) and the investor webcasts ( first study
webcast ), ( second study webcast ) which are available for replay on the
Notes to the editor
About the Phase 3 registration program
The Phase 3 registration program comprises two confirmatory studies of 3-month
duration, together with a long-term extension study. Both pivotal studies are
complete, having enrolled around 1,850 patients with insomnia at over 160 sites
across 18 countries. As insomnia often presents later in life, around 40% of
the recruited population was aged 65 years or older. The confirmatory
multi-center, double-blind, randomized, placebo-controlled, parallel-group,
polysomnography studies investigated three doses of daridorexant (10 mg, 25 mg,
and 50 mg) on sleep and daytime functioning parameters, objectively in a sleep
lab by polysomnography and subjectively with a daily patient diary at home.
The impact of insomnia on patients’ daytime functioning was measured daily
using the sleepiness domain score from the Insomnia Daytime Symptoms and
Impacts Questionnaire (IDSIQ) a Patient Reported Outcome (PRO) instrument,
validated according to the US Food and Drug Administration (FDA) Guidance for
Industry. 806 patients decided to continue treatment in the ongoing 40-week
extension study which will measure the effect of all three doses vs. placebo,
generating data for long-term treatment of insomnia.
Insomnia is defined as a combination of dissatisfaction with sleep and a
significant negative impact on daytime performance. Dissatisfaction with sleep
refers to the difficulty to initiate and/or maintain sleep on at least three
nights per week for at least three months, despite adequate opportunity to
Insomnia is, worldwide, the most commonly reported sleep disorder and its
impact is often underestimated. In reality, it can be a distressing condition
that can impair quality of life. Sleepless nights can leave people feeling
irritable and out of sorts – this may affect many aspects of daily life, from
studying and employment to social activities and relationships. People who
suffer from insomnia may lack the energy or motivation to exercise or to take
part in social activities. It can also have a significant economic impact as it
increases the risk of accident and injury on the road or in the workplace, and
is a leading cause of absenteeism and reduced productivity at work. People with
insomnia are more likely to experience feeling down or depressed, lack
concentration, and suffer from poor energy levels during the day compared with
people who sleep well. In addition, worrying about sleep can cause stress and
may lead to negative thought patterns which may in turn make it more difficult
to sleep, setting up a vicious cycle. Chronic insomnia is associated with
cardiovascular and cerebrovascular diseases, and increased mortality.
The goal of treatment for insomnia is to improve sleep quality and quantity,
as well as to reduce insomnia-related impaired daytime performance, while
avoiding adverse events and next morning residual effects. Current treatment of
insomnia includes cognitive behavioral therapy, sleep hygiene recommendations,
and pharmacotherapy. The most widely prescribed products on the market that are
indicated for insomnia enhance the effects of gamma-aminobutyric acid (GABA),
the major inhibitory neurotransmitter in the central nervous system. Such
medications are only approved for short-term use and are associated with side
effects such as next-day effects, anterograde amnesia, and risk of tolerance
About Dr. Thomas Roth, PhD
Dr. Roth has been the Director of the Sleep Disorders and Research Center at
Henry Ford Hospital in Detroit, since 1978. Dr. Roth is also a Professor in the
Department of Psychiatry at Wayne State University, School of Medicine in
Detroit, Michigan, and serves as a Clinical Professor in the Department of
Psychiatry at the University of Michigan, College of Medicine in Ann Arbor.
After serving as president of the Sleep Research Society, and the founding
president of the National Sleep Foundation (NSF), Dr. Roth became chairman of
the National Center on Sleep Disorders Research advisory board. In addition, he
was a member of the board of directors of the Associated Professional Sleep
Societies (APSS), chaired the Association's Scientific Program Committee and
the governing board of the World Federation of Sleep Research Societies.
Dr. Roth was instrumental in the formation of the Association of Sleep
Disorders Center (ASDC) and served as the organization's second president. He
is also the former Chairman of the World Health Organization's worldwide
project on sleep and health. In addition to authoring and co-authoring numerous
articles, Dr. Roth serves as past editor-in-chief of the journal Sleep. He
currently sits on the editorial boards of Sleep Reviews, Stress Medicine, and
Advances in Therapy and Human Psychopharmacology.
In 2002, Dr. Roth received the NSF's Lifetime Achievement Award for his
accomplishments and contributions to sleep science, sleep medicine and public
health. He received a Distinguished Research Award from the Sleep Research
Society as well as the Nathanial Kleitman Award from the Academy of Sleep
Medicine. Dr. Roth's contributions to the sleep field are expansive, ranging
from prolific research productivity and scholarship to multiple national
leadership positions, as well as the mentoring of many students and colleagues.
Dr. Roth serves as a consultant to Idorsia.
Idorsia Ltd is reaching out for more - We have more ideas, we see more
opportunities and we want to help more patients. In order to achieve this, we
will develop Idorsia into one of Europe’s leading biopharmaceutical companies,
with a strong scientific core.
Headquartered in Switzerland - a biotech-hub of Europe - Idorsia is
specialized in the discovery and development of small molecules, to transform
the horizon of therapeutic options. Idorsia has a broad portfolio of innovative
drugs in the pipeline, an experienced team, a fully-functional research center,
and a strong balance sheet – the ideal constellation to bringing R&D efforts to
Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June
2017 and has over 800 highly qualified specialists dedicated to realizing our
For further information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
The above information contains certain 'forward-looking statements', relating
to the company's business, which can be identified by the use of
forward-looking terminology such as 'estimates', 'believes', 'expects', 'may',
'are expected to', 'will', 'will continue', 'should', 'would be', 'seeks',
'pending' or 'anticipates' or similar expressions, or by discussions of
strategy, plans or intentions. Such statements include descriptions of the
company's investment and research and development programs and anticipated
expenditures in connection therewith, descriptions of new products expected to
be introduced by the company and anticipated customer demand for such products
and products in the company's existing portfolio. Such statements reflect the
current views of the company with respect to future events and are subject to
certain risks, uncertainties and assumptions. Many factors could cause the
actual results, performance or achievements of the company to be materially
different from any future results, performances or achievements that may be
expressed or implied by such forward-looking statements. Should one or more of
these risks or uncertainties materialize, or should underlying assumptions
prove incorrect, actual results may vary materially from those described herein
as anticipated, believed, estimated or expected.
Anhang Medienmitteilung PDF